NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Cue Biopharma, Inc. CUE
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$27.5M
▲ 195.7% vs FY2024
EPS · FY25
$-0.28
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-121.1%
Net margin · FY25
-96.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 27.5M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 97 cents on every revenue dollar this year.
Per share
USD -0.28
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-121.1%
Return on equity, FY2025
ROE
Operating margin-96.7%
Net margin-96.9%
Return on assets-71.5%
Each USD of equity lost 121 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+54.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+180.5%
+54.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+132.7%
Change, 10 years—
The share count grew 133% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 42.2M
total assets, end of FY2025
Total assetsUSD 42.2M
EquityUSD 26.4M
CashUSD 27.1M
Current ratio2.74×
Equity funds 63% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.28
−0.72
−1.11
−1.49
−1.41
−1.56
−1.66
−1.94
−2.16
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−121.1
−149.0
−98.7
−80.8
−61.2
−67.1
−82.9
−81.6
−37.7
Shares out B
0.10
0.06
0.05
0.05
0.03
0.03
0.03
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed